24 Development of novel therapies for hepatitis C

Biomedical Research Reports

Volumn 2, Issue C, 2000, Pages 453-467

  Lau, Johnson Y N ^a,b   Standring, David N ^a,b  

^a Department of Research and Development ICN Pharmaceuticals Costa Mesa ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957030454     PISSN: 18745326     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5326(00)80028-9     Document Type: Article

References (47)

1. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 59-362
2. Kuo G., Choo Q.L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B-hepatitis. Science 244 (1989) 362-364
3. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321 (1989) 1501-1506
4. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1485-1492
5. Poynard T., Marcellin P., Lee S.S., et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
6. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1493-1499
7. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., and Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 25 277 (1997) 570-574
8. Yanagi M., St Claire M., Shapiro M., Emerson S.U., Purcell R.H., and Bukh J. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244 (1998) 161-172
9. Hong Z., Beaudet-Miller M., Lanford R.E., et al. Generation of transmissible hepatitis C virions from a molecular clone in Chimpanzees. Virology 256 (1999) 36-44
10. Robertson B., Myers G., Howard C., et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143 (1998) 2493-2503
11. Grakoui A., Wychowski C., Lin C., Feinstone S.M., and Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67 (1993) 1385-1395
12. Brown E.A., Zhang H., Ping L.H., and Lemon S.M. Secondary structure of the 5′ nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 20 (1992) 5041-5045
13. Zapp M.L., Stern S., and Green M.R. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74 (1993) 969-978
14. Hwang S.B., Lo S.Y., Ou J.H., and Lai M.M.C. Detection of cellular proteins and viral core protein interacting with the 5′ untranslated region of hepatitis C virus RNA. J Biomed Sci 2 (1995) 227-236
15. Zhu N., Khoshnan A., Schneider R., et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 72 (1998) 3691-3697
16. Lo S.Y., Masiarz F., Hwang S.B., et al. Differential subcellular localization of hepatitis C virus core gene products. Virology 213 (1995) 455-461
17. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
18. Labrosse B., Brelot A., Heveker N., et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72 (1998) 6381-6388
19. Kilby J.M., Hopkins S., Venetta T.M., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4 (1998) 1302-1307
20. Ggrakoui A., McCourt D.W., Wychowski C., Feinstone S.M., and Rice C.M. Characterization of the hepatitis C virus-encoded serine protease: determination of proteinase-dependent polyprotein cleavage. J Virol 67 (1993) 2832-2843
21. Bartenschlager R., Rhlborn-Laake L., Mous J., and Jacobson H. Kinetics and structural analysis of hepatitis C virus polyprotein processing. J Virol 68 (1994) 5045-5055
22. Satoh S., Tanji Y., Hijikata M., Kimura K., and Shimotohno K. The N-terminal region of hepatitis C virus non-structural protein (NS3) is essential for stable complex formation with NS4A. J Virol 69 (1995) 4255-4260
23. Kim J.L., Morgenstern K.A., Lin C., et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87 (1996) 343-355
24. Kadare G., and Haenni A.L. Virus-encoded RNA helicases. J Virol 71 (1997) 2583-2590
25. Fernandez A., Guo H.S., Saenz P., Simon-Buela L., Gomez de Cedron M., and Garcia J.A. The motif V of plum pox potyvirus CI RNA helicase is involved in NTP hydrolysis and is essential for virus RNA replication. Nucleic Acids Res 25 (1997) 4474-4480
26. Warrener P., and Collett M.S. Pestivirus NS3 (p80) protein possesses RNA helicase activity. J Virol 69 (1995) 1720-1726
27. Tai C.L., Chi W.K., Chen D.S., and Hwang L.H. The helicase acctivity associated with hepatitis C virus non-structural protein 3 (NS3). J Virol 70 (1996) 8477-8484
28. Yao N., Hesson T., Cable M., et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 4 (1997) 463-467
29. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334 (1996) 77-81
30. Gale Jr. M.J., Korth M.J., Tang N.M., et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
31. Behrens S.E., Tomei L., and De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 15 (1996) 12-22
32. Lohmann V., Korner F., Herian U., and Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 71 (1997) 8416-8428
33. Ferrari E., Wright-Minogue J., Fang J.W., Baroudy B.M., Lau J.Y., and Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 73 (1999) 1649-1654
34. Ito T., and Lai M.M. Determination of the secondary structure of and cellular protein binding to the 3′-untranslated region of the hepatitis C virus RNA genome. J Virol 71 (1997) 8698-8706
35. Takamizawa A., Mori C., Fuke I., et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 65 (1991) 1105-1113
36. Kolykhalov A.A., Feinstone S.M., and Rice C.M. Identification of a highly conserved sequence element at the 3′terminus of hepatitis C virus genome RNA. J Virol 70 (1996) 3363-3371
37. Nelson D.R., Marousis C.G., Davis G.L., et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158 (1997) 1473-1481
38. Diepolder H.M., Zachoval R., Hoffmann R.M., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C. Lancet 346 (1995) 1006-1007
39. Nelson D.R., Marousis C.G., Ohno T., Davis G.L., and Lau J. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28 (1998) 225-230
40. Lohr H.F., Gerken G., Roth M., et al. The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. J Hepatol 29 (1998) 524-532
41. Houghton M., Choo Q.L., Kuo G., et al. HCV Vaccine: interim report. 9th Trienn Int Symp Viral Hepatitis Liver Dis. Rome, April (1996)
42. Maertens G., Ducatteeuw A., Priem S., et al. Therapeutic vaccination of chronically infected chimpanzees with the HCV E1 protein. Hepatology 28 (1998) 298A
43. Sarobe P., Pendleton C.D., Akatsuka T., et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 15 (1998) 1239-1248
44. Geissler M., Tokushige K., Wakita T., Zurawski Jr. V.R., and Wands J.R. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 16 (1998) 857-867
45. Encke J., zu Putlitz J., Geissler M., and Wands J.R. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 161 (1998) 4917-4923
46. Chapter 10. Dailey P.J., Collins M.L., Urdea M.S., and Wilber J.C. Quantitation of HCV RNA in liver tissue by bDNA. In: Lau J. (Ed). Hepatitis C protocols (1998), Humana Press, Clifton, NJ 119-129
47. Roberts E.C., Malmstrom T.A., Pavco P.A., et al. Synthesis and testing of nuclease resistant hammerhead ribozymes directed against hepatitis C virus RNA. Hepatology 28 (1998) 398A